<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259168</url>
  </required_header>
  <id_info>
    <org_study_id>02-005/03</org_study_id>
    <nct_id>NCT00259168</nct_id>
  </id_info>
  <brief_title>Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?</brief_title>
  <official_title>Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether attenuation/normalization of elevated blood
      sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin
      resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:Insulin Resistance (IR) is accompanied by a high incidence and prevalence of
      cardiovascular disease. IR is present in individuals with pre-diabetes/ type 2 diabetes.
      Epidemiological data demonstrate a tight relationship between postprandial blood sugar,
      insulin resistance and cardiovascular disease (CVD). Endothelial dysfunction seems to be the
      very first sign of CVD.

      Purpose: We propose to determine whether attenuation /normalization of post-prandial
      hyperglycaemia, through the administration of an oral hypoglycaemic agent of ultra rapid
      action (nateglinide), ameliorates endothelial function in the IR.

      We extrapolate that a better endothelial function in the brachial artery reflects regression
      of atherosclerotic changes in the coronary system.

      Method and Study Design: Prospective, open, parallel, group comparison study of 1
      intervention group, 1 intervention control group and 1 disease control group. The
      intervention group and the intervention control group each consist of 30 individuals with IR.
      Individuals in the intervention group receive an individually adjusted dose of nateglinide 3
      times daily during 12 weeks. The third group consists of 10 healthy, young individuals. All
      groups are followed during 3 months with an otherwise unchanged lifestyle. Endothelial
      function is measured with the Flow Mediated Dilation method before and after the
      intervention/observation period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic function</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Impaired Fasting Glucose</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nateglinide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insulin resistance, impaired glucose tolerance

        Exclusion Criteria:

          -  unstable chronic disease, acute disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christian Torp-Pedersen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atheline Major-Pedersen, MD</last_name>
    <phone>35316160</phone>
    <email>atmp@heart.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endothelial laboratory, Cardiology clinic Y-research, H:S Bispebjerg Hospital</name>
      <address>
        <city>Bispebjerg Bakke, Copenhagen</city>
        <state>Copenhagen NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atheline Major-Pedersen, MD</last_name>
      <phone>35316160</phone>
      <email>atmp@heart.dk</email>
    </contact>
    <contact_backup>
      <last_name>Christian Torp-Pedersen, MD, DMSc</last_name>
      <phone>35316159</phone>
      <email>ctp@heart.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Atheline Major-Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolaj Ihlemann, MD, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas S Hermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Dominguez, MD, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Britt Kveiborg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Buris Christiansen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Rask-Madsen, MD, Phd</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ole L Svendsen, MD, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars KÃ¸ber, MD, DMsc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorthe B Braunberg, Lab tech.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Torp-Pedersen, MD, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002 Sep 3;106(10):1211-8.</citation>
    <PMID>12208795</PMID>
  </reference>
  <reference>
    <citation>Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.</citation>
    <PMID>1359209</PMID>
  </reference>
  <reference>
    <citation>Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082.</citation>
    <PMID>11788217</PMID>
  </reference>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>November 28, 2005</last_update_submitted>
  <last_update_submitted_qc>November 28, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2005</last_update_posted>
  <keyword>Postprandial endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nateglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

